Abstract
Background: Peritoneal carcinomatosis (PC) is an adverse prognostic factor for several cancers. CRS/HIPEC is considered a standard option for primary peritoneal tumors as well as ovarian cancer, and can be considered in selected gastric and colorectal cancer patients. The safety and efficacy of CRS/HIPEC have not been fully evaluated in pts beyond these indications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
